165 related articles for article (PubMed ID: 25029972)
1. Orphan therapies: making best use of postmarket data.
Maro JC; Brown JS; Dal Pan GJ; Li L
J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S745-51. PubMed ID: 25029972
[TBL] [Abstract][Full Text] [Related]
2. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
3. The challenges of pharmacoepidemiology of orphan drugs in rare diseases.
Lapeyre-Mestre M
Therapie; 2020 Apr; 75(2):215-220. PubMed ID: 32164974
[TBL] [Abstract][Full Text] [Related]
4. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products.
Sirrs SM; Arthus MF; Bichet DG; Rockman-Greenberg C; LeMoine K; Morel CF; Lachmann R; Lynd LD; Wasim S; West ML; Hollak C
Value Health; 2021 Feb; 24(2):268-273. PubMed ID: 33518033
[TBL] [Abstract][Full Text] [Related]
5. Strategies for postmarketing surveillance of drugs for rare diseases.
Kesselheim AS; Gagne JJ
Clin Pharmacol Ther; 2014 Mar; 95(3):265-8. PubMed ID: 24193169
[TBL] [Abstract][Full Text] [Related]
6. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers AE; Moors EH; van Weely S; de Vrueh RL
Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
[TBL] [Abstract][Full Text] [Related]
7. Ethical considerations in orphan drug approval and use.
Kesselheim AS
Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
[TBL] [Abstract][Full Text] [Related]
8. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
[TBL] [Abstract][Full Text] [Related]
9. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
Maro JC; Brown JS
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
[TBL] [Abstract][Full Text] [Related]
10. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
Crisafulli S; Sultana J; Ingrasciotta Y; Addis A; Cananzi P; Cavagna L; Conter V; D'Angelo G; Ferrajolo C; Mantovani L; Pastorello M; Scondotto S; Trifirò G
Expert Opin Drug Saf; 2019 Jun; 18(6):497-509. PubMed ID: 31059293
[TBL] [Abstract][Full Text] [Related]
11. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
12. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators.
Bates J; Parzynski CS; Dhruva SS; Coppi A; Kuntz R; Li SX; Marinac-Dabic D; Masoudi FA; Shaw RE; Warner F; Krumholz HM; Ross JS
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):848-856. PubMed ID: 29896873
[TBL] [Abstract][Full Text] [Related]
13. Adopting an orphan.
Rinaldi A
EMBO Rep; 2005 Jun; 6(6):507-10. PubMed ID: 15940282
[TBL] [Abstract][Full Text] [Related]
14. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic profile of orphan medicines.
de Barros CM; Papoila AL
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):435-40. PubMed ID: 16958155
[TBL] [Abstract][Full Text] [Related]
16. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
Smith RJ; Hiatt WR
JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296
[No Abstract] [Full Text] [Related]
17. Rare disease resources not as rare as one might think.
Burnworth MT
Am J Health Syst Pharm; 2013 Jun; 70(12):1013-4. PubMed ID: 23719873
[No Abstract] [Full Text] [Related]
18. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.
Hollak CE; Aerts JM; Aymé S; Manuel J
Orphanet J Rare Dis; 2011 Apr; 6():16. PubMed ID: 21496291
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
Micallef J; Boutouyrie P; Blin O
Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
